Results of the National Lung Cancer Screening Trial: Where Are We Now?

Overview

Journal Thorac Surg Clin

Publisher Elsevier

Specialties General Surgery
Pulmonary Medicine

Date 2015 Apr 23

PMID 25901558

Citations 11

Authors

Neel P Chudgar

Peter R Bucciarelli

Elizabeth M Jeffries

Nabil P Rizk

Bernard J Park

Prasad S Adusumilli

David R Jones

Affiliations

Soon will be listed here.

Abstract

The National Lung Screening Trial was a large, multicenter, randomized controlled trial published in 2011. It found that annual screening with low-dose CT (LDCT) in a high-risk population was associated with a 20% reduction in lung cancer-specific mortality compared with conventional chest radiography. Several leading professional organizations have since put forth lung cancer screening guidelines that include the use of LDCT, largely on the basis of this study. Broad adoption of these screening recommendations, however, remains a challenge.

Citing Articles

Lung Cancer-Epidemiology, Pathogenesis, Treatment and Molecular Aspect (Review of Literature).

Smolarz B, Lukasiewicz H, Samulak D, Piekarska E, Kolacinski R, Romanowicz H Int J Mol Sci. 2025; 26(5).

PMID: 40076671 PMC: 11900952. DOI: 10.3390/ijms26052049.

Economic Evaluation of a Novel Lung Cancer Diagnostic in a Population of Patients with a Positive Low-Dose Computed Tomography Result.

Morris M, Habib S, Do Valle M, Schneider J J Health Econ Outcomes Res. 2025; 11(2):74-79.

PMID: 39810799 PMC: 11731590. DOI: 10.36469/001c.121512.

Vascular Biomarkers for Pulmonary Nodule Malignancy: Arteries vs. Veins.

Yu T, Zhao X, Leader J, Wang J, Meng X, Herman J Cancers (Basel). 2024; 16(19.

PMID: 39409894 PMC: 11476001. DOI: 10.3390/cancers16193274.

The Effect of COVID-19 on Lung Cancer Screening.

Thiruppathi N, Humphries N, Johnson S, Tunison L, Pippas A Cureus. 2024; 16(9):e68986.

PMID: 39385861 PMC: 11463903. DOI: 10.7759/cureus.68986.

The cognitive and perceptual processes that affect observer performance in lung cancer detection: a scoping review.

Van De Luecht M, Reed W J Med Radiat Sci. 2021; 68(2):175-185.

PMID: 33556995 PMC: 8168065. DOI: 10.1002/jmrs.456.

References

Wender R, Fontham E, Barrera Jr E, Colditz G, Church T, Ettinger D . American Cancer Society lung cancer screening guidelines. CA Cancer J Clin. 2013; 63(2):107-17. PMC: 3632634. DOI: 10.3322/caac.21172. View

Bach P, Gould M . When the average applies to no one: personalized decision making about potential benefits of lung cancer screening. Ann Intern Med. 2012; 157(8):571-3. DOI: 10.7326/0003-4819-157-8-201210160-00524. View

Villanti A, Jiang Y, Abrams D, Pyenson B . A cost-utility analysis of lung cancer screening and the additional benefits of incorporating smoking cessation interventions. PLoS One. 2013; 8(8):e71379. PMC: 3737088. DOI: 10.1371/journal.pone.0071379. View

Aberle D, DeMello S, Berg C, Black W, Brewer B, Church T . Results of the two incidence screenings in the National Lung Screening Trial. N Engl J Med. 2013; 369(10):920-31. PMC: 4307922. DOI: 10.1056/NEJMoa1208962. View

Siegel R, Ma J, Zou Z, Jemal A . Cancer statistics, 2014. CA Cancer J Clin. 2014; 64(1):9-29. DOI: 10.3322/caac.21208. View

Pinsky P, Church T, Izmirlian G, Kramer B . The National Lung Screening Trial: results stratified by demographics, smoking history, and lung cancer histology. Cancer. 2013; 119(22):3976-83. PMC: 3936005. DOI: 10.1002/cncr.28326. View

Pace L, Keating N . A systematic assessment of benefits and risks to guide breast cancer screening decisions. JAMA. 2014; 311(13):1327-35. DOI: 10.1001/jama.2014.1398. View

Moyer V . Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014; 160(5):330-8. DOI: 10.7326/M13-2771. View

de Koning H, Meza R, Plevritis S, Ten Haaf K, Munshi V, Jeon J . Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task Force. Ann Intern Med. 2014; 160(5):311-20. PMC: 4116741. DOI: 10.7326/M13-2316. View

10.

Detterbeck F, Unger M . Screening for lung cancer: moving into a new era. Ann Intern Med. 2014; 160(5):363-4. DOI: 10.7326/M13-2904. View

11.

Bach P . Raising the bar for the U.S. Preventive Services Task Force. Ann Intern Med. 2014; 160(5):365-6. DOI: 10.7326/M13-2926. View

12.

Weinberg D, Schoen R . In the clinic. Screening for colorectal cancer. Ann Intern Med. 2014; 160(9). DOI: 10.7326/0003-4819-160-9-201405060-01005. View

13.

Brawley O, Flenaugh E . Low-dose spiral CT screening and evaluation of the solitary pulmonary nodule. Oncology (Williston Park). 2014; 28(5):441-6. View

14.

DeSantis C, Lin C, Mariotto A, Siegel R, Stein K, Kramer J . Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014; 64(4):252-71. DOI: 10.3322/caac.21235. View

15.

Wiener R . Balancing the benefits and harms of low-dose computed tomography screening for lung cancer: Medicare's options for coverage. Ann Intern Med. 2014; 161(6):445-6. DOI: 10.7326/M14-1352. View

16.

BERLIN N . Overview of the NCI Cooperative Early Lung Cancer Detection Program. Cancer. 2001; 89(11 Suppl):2349-51. DOI: 10.1002/1097-0142(20001201)89:11+<2349::aid-cncr6>3.3.co;2-w. View

17.

Wender R, Smith R, Harper D . Cancer screening. Prim Care. 2003; 29(3):697-725. DOI: 10.1016/s0095-4543(02)00019-2. View

18.

Baig N, Myers R, Turner B, Grana J, Rothermel T, Schlackman N . Physician-reported reasons for limited follow-up of patients with a positive fecal occult blood test screening result. Am J Gastroenterol. 2003; 98(9):2078-81. DOI: 10.1111/j.1572-0241.2003.07575.x. View

19.

Pastorino U, Bellomi M, Landoni C, De Fiori E, Arnaldi P, Picchio M . Early lung-cancer detection with spiral CT and positron emission tomography in heavy smokers: 2-year results. Lancet. 2003; 362(9384):593-7. DOI: 10.1016/S0140-6736(03)14188-8. View

20.

Swensen S, Jett J, Hartman T, Midthun D, Sloan J, Sykes A . Lung cancer screening with CT: Mayo Clinic experience. Radiology. 2003; 226(3):756-61. DOI: 10.1148/radiol.2263020036. View